Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria

NCT03520036 is registered in ClinicalTrials.gov with Tanabe Pharma America, Inc. as lead sponsor.

NCT NCT03520036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03520036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria
Lead sponsor
Tanabe Pharma America, Inc.
Phase
Phase 2
Overall status
Completed
Start date
July 5, 2018
Completion date
September 28, 2019
Enrollment
102 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

erythropoietic protoporphyria (epp)